|
|
Article: Immune Response Stock Dips After Study.(securities information)(Brief Article)(Statistical Data Included)
- Article from:
- San Diego Business Journal
- Article date:
- November 13, 2000
- Author:
CopyrightCOPYRIGHT 2000 CBJ, L.P. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Shares of Immune Response Corp. continued to hover in the $4 range the week after publication of an unfavorable university study of its AIDS drug, Remune.
The publication of the three-year study in The Journal of the American Medical Association led the firm to file legal action against the University of California, San Francisco, and Dr. James O. Kahn, the author and leading investigator of the study.
Shares of the Carlsbad-based biotechnology firm fell 19 cents to $4.44 on Nov. 8 from $4.63 on Nov. 1, the day the article ran.
James McCamant, editor of the Berkeley-based Medical Technology Stock Letter, said some investors may have had ...